Mylan has agreed to purchase the global marketing rights of GA Depot from Mapi Pharma.
Mylan will invest $20m in Mapi Pharma, as part of the transaction.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Both companies will collaborate on the development and commercialisation of GA Depot, an injectable formulation used for the treatment of multiple sclerosis.
Based in the UK, Mylan is a pharmaceutical company, while Mapi Pharma is a clinical-stage pharmaceutical company based in Israel.
Italian pharmaceutical company Recordati has purchased the rights to Cystagon (cysteamine bitartrate) in Europe from Mylan.
Cystagon is indicated for the treatment of nephropathic cystinosis in children and adults.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBased in the UK, Mylan is both a generic and specialist pharmaceutical company.
Pharmaceutical company Mylan has issued senior notes in a private placement to raise $750m.
Due 2028, the notes carry an interest rate of 5.2% a year and have been subscribed to by institutional investors.
Mylan has simultaneously issued 4.55% senior notes due 2028 in a private placement to raise $750m.
The placement was subscribed to by individuals outside the US.
Mylan plans to use the proceeds from the placements for repaying debt.
US-based biopharmaceutical company MannKind has completed the private placement of 14 million shares of its common stock and warrants priced at $2 a share to raise $28m.
Certain healthcare-dedicated institutional investors have subscribed to the placement.
The company plans to use the proceeds for general corporate purposes, including expenses related to production, clinical trials, research and development, sales and marketing. It will also use the funds for marketing of Afrezza and other product candidates.
H.C. Wainwright & Co was appointed as placement agent, and Greenhill & Co. was appointed as financial adviser for the transaction.
